多倍体巨型癌细胞：揭示her2靶向治疗的潜在耐药轴和肿瘤进化。

IF 10.1 1区医学 Q1 ONCOLOGY

Cancer letters Pub Date : 2025-09-01 DOI:10.1016/j.canlet.2025.217998

Madhan Krishnan, Shyamaladevi Babu

{"title":"多倍体巨型癌细胞：揭示her2靶向治疗的潜在耐药轴和肿瘤进化。","authors":"Madhan Krishnan, Shyamaladevi Babu","doi":"10.1016/j.canlet.2025.217998","DOIUrl":null,"url":null,"abstract":"<div><div>Recent findings by Yazdi et al. in <em>Cancer Letters</em> present a mechanistic breakthrough in understanding resistance to HER2-targeting antibody-drug conjugates (ADCs). Their identification of drug-persistent polyploid giant cancer cells (PGCCs) as active participants in resistance redefines our understanding of intratumoral plasticity and therapeutic evasion. Far from being senescent relics, PGCCs function as epigenetically plastic reservoirs of tumor regeneration, capable of entering dormancy and re-seeding therapy-resistant clones. This commentary explores the mechanistic, evolutionary, and clinical implications of this phenomenon, urging a shift toward integrated therapeutic designs that disrupt the adaptive survival circuitry of PGCCs.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"631 ","pages":"Article 217998"},"PeriodicalIF":10.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Polyploid giant cancer cells: Unveiling a latent axis of resistance and tumor evolution in HER2-targeted therapy\",\"authors\":\"Madhan Krishnan, Shyamaladevi Babu\",\"doi\":\"10.1016/j.canlet.2025.217998\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Recent findings by Yazdi et al. in <em>Cancer Letters</em> present a mechanistic breakthrough in understanding resistance to HER2-targeting antibody-drug conjugates (ADCs). Their identification of drug-persistent polyploid giant cancer cells (PGCCs) as active participants in resistance redefines our understanding of intratumoral plasticity and therapeutic evasion. Far from being senescent relics, PGCCs function as epigenetically plastic reservoirs of tumor regeneration, capable of entering dormancy and re-seeding therapy-resistant clones. This commentary explores the mechanistic, evolutionary, and clinical implications of this phenomenon, urging a shift toward integrated therapeutic designs that disrupt the adaptive survival circuitry of PGCCs.</div></div>\",\"PeriodicalId\":9506,\"journal\":{\"name\":\"Cancer letters\",\"volume\":\"631 \",\"pages\":\"Article 217998\"},\"PeriodicalIF\":10.1000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0304383525005683\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304383525005683","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Yazdi等人最近在《癌症快报》（Cancer Letters）上的发现在理解her2靶向抗体-药物偶联物（adc）耐药性方面取得了机制上的突破。他们发现药物持久性多倍体巨癌细胞（PGCCs）在耐药过程中起着积极的作用，这重新定义了我们对肿瘤内可塑性和治疗逃避的理解。pgcc远不是衰老的遗物，而是肿瘤再生的表观遗传可塑性储存库，能够进入休眠状态并重新播种抗治疗克隆。这篇评论探讨了这一现象的机制、进化和临床意义，敦促向破坏pgcc适应性生存回路的综合治疗设计转变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Polyploid giant cancer cells: Unveiling a latent axis of resistance and tumor evolution in HER2-targeted therapy

Recent findings by Yazdi et al. in Cancer Letters present a mechanistic breakthrough in understanding resistance to HER2-targeting antibody-drug conjugates (ADCs). Their identification of drug-persistent polyploid giant cancer cells (PGCCs) as active participants in resistance redefines our understanding of intratumoral plasticity and therapeutic evasion. Far from being senescent relics, PGCCs function as epigenetically plastic reservoirs of tumor regeneration, capable of entering dormancy and re-seeding therapy-resistant clones. This commentary explores the mechanistic, evolutionary, and clinical implications of this phenomenon, urging a shift toward integrated therapeutic designs that disrupt the adaptive survival circuitry of PGCCs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer letters 医学-肿瘤学

CiteScore

17.70

自引率

2.10%

发文量

427

审稿时长

15 days

期刊介绍： Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research. Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy. By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.